Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
51.4M
-
Shares change
-
+2.85M
-
Total reported value, excl. options
-
$1.51B
-
Value change
-
+$73.7M
-
Put/Call ratio
-
0.2
-
Number of buys
-
98
-
Number of sells
-
-57
-
Price
-
$29.34
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q1 2023
189 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q1 2023.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.4M shares
of 111M outstanding shares and own 46.37% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (6.03M shares), VANGUARD GROUP INC (4.75M shares), BlackRock Inc. (3.61M shares), VIKING GLOBAL INVESTORS LP (2.96M shares), Boxer Capital, LLC (2.08M shares), D. E. Shaw & Co., Inc. (2.02M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.98M shares), FEDERATED HERMES, INC. (1.85M shares), Rock Springs Capital Management LP (1.45M shares), and PICTET ASSET MANAGEMENT SA (1.43M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.